Next-Generation ON-Bipolar-Targeted Optogenetic Therapy Using Enhanced Photosensitive Protein and Promoter Achieves Durable Vision Restoration in Retinal Degeneration (ASGCT 2026) - Mar 22, 2026 - Abstract #185; 1819; Pres time: May 13, 2026; 11:00 AM - 11:15 AM; Location: MCEC Room 205ABC (Level 2); "This study aimed to determine whether these innovations could provide long- term, safe, and meaningful visual restoration in a severe retinal degeneration model, building on the first-in-human experience of our previous product ZM-02, which has received IIT and IND clearance...(c) Photoresponses of retinal bipolar cells upon exposure to 470 nm, 530 nm, and 590 nm light at different light intensities, scale bar = 20 pA,1s. (d) Statistical analysis of peak photocuurrent in retinal bipolar cells at varied light intensities and wavelengths."
First-in-human • CNS Disorders • Gene Therapies • Infectious Disease • Ophthalmology • PRKCA
|
|
Lingbo Zhou1; Yu Li1; Sanwei Jiang2; Qiulin Song1; Shiqiang Gao3; Yang Wu4; Sen Jin2; Jingjing Cao2; Yin Shen1
|